Literature DB >> 26700797

Genetic association of CALHM1 rs2986017 polymorphism with risk of Alzheimer's disease: a meta-analysis.

Yanjun Lu1, Wei Liu2, Kun Tan3, Jing Peng1, Yaowu Zhu1, Xiong Wang4.   

Abstract

Recent studies investigating the association of Calcium homeostasis modulator 1 (CALHM1) p.P86L polymorphism (rs2986017) with Alzheimer's disease (AD) are controversial. Herein, we performed a meta-analysis to investigate the association between CALHM1 rs2986017 and AD risk. Literature searches of PubMed, Alzgene, and Embase were carried out up to 24 Nov 2015. The strength of the association between rs2986017 and AD was evaluated by odds ratio (OR) and 95 % confidence interval (CI). A total of 19 studies between 2008 and 2014 comprising 8777 AD cases and 8487 controls were included. Significant association of rs2986017 with AD was found in Caucasian population in allelic model (T vs. C: OR 1.13, 95 % CI 1.02-1.26, P = 0.022), and dominant model (TT + TC vs. CC: OR 1.15, 95 % CI 1.04-1.29, P = 0.018). No significant association was found in Asian population in any genetic model. Sensitivity analysis found that Dreses-Werringloer et al.'s might affect the overall result. The current meta-analysis suggested that CALHM1 rs2986017 might be associated with increased AD risk in Caucasian, but not Asian population.

Entities:  

Keywords:  Alzheimer’s disease; CALHM1; Meta-analysis; Polymorphism; rs2986017

Mesh:

Substances:

Year:  2015        PMID: 26700797     DOI: 10.1007/s10072-015-2451-3

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  23 in total

1.  A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk.

Authors:  Ute Dreses-Werringloer; Jean-Charles Lambert; Valérie Vingtdeux; Haitian Zhao; Horia Vais; Adam Siebert; Ankit Jain; Jeremy Koppel; Anne Rovelet-Lecrux; Didier Hannequin; Florence Pasquier; Daniela Galimberti; Elio Scarpini; David Mann; Corinne Lendon; Dominique Campion; Philippe Amouyel; Peter Davies; J Kevin Foskett; Fabien Campagne; Philippe Marambaud
Journal:  Cell       Date:  2008-06-27       Impact factor: 41.582

2.  CALHM1 P86L polymorphism modulates CSF Aβ levels in cognitively healthy individuals at risk for Alzheimer's disease.

Authors:  Jeremy Koppel; Fabien Campagne; Valérie Vingtdeux; Ute Dreses-Werringloer; Michael Ewers; Dan Rujescu; Harald Hampel; Marc L Gordon; Erica Christen; Julien Chapuis; Blaine S Greenwald; Peter Davies; Philippe Marambaud
Journal:  Mol Med       Date:  2011-05-24       Impact factor: 6.354

Review 3.  Genetics of Alzheimer's disease.

Authors:  Vincent Chouraki; Sudha Seshadri
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

4.  The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis study.

Authors:  Jean-Charles Lambert; Kristel Sleegers; Antonio González-Pérez; Martin Ingelsson; Gary W Beecham; Mikko Hiltunen; Onofre Combarros; Maria J Bullido; Nathalie Brouwers; Karolien Bettens; Claudine Berr; Florence Pasquier; Florence Richard; Steven T Dekosky; Didier Hannequin; Jonathan L Haines; Gloria Tognoni; Nathalie Fiévet; Jean-François Dartigues; Christophe Tzourio; Sebastiaan Engelborghs; Beatrice Arosio; Elicer Coto; Peter De Deyn; Maria Del Zompo; Ignacio Mateo; Merce Boada; Carmen Antunez; Jesus Lopez-Arrieta; Jacques Epelbaum; Brit-Maren Michaud Schjeide; Ana Frank-Garcia; Vilmentas Giedraitis; Seppo Helisalmi; Elisa Porcellini; Alberto Pilotto; Paola Forti; Raffaele Ferri; Marc Delepine; Diana Zelenika; Mark Lathrop; Elio Scarpini; Gabriele Siciliano; Vincenzo Solfrizzi; Sandro Sorbi; Gianfranco Spalletta; Giovanni Ravaglia; Fernando Valdivieso; Saila Vepsäläinen; Victoria Alvarez; Paolo Bosco; Michelangelo Mancuso; Francesco Panza; Benedetta Nacmias; Paola Bossù; Olivier Hanon; Paola Piccardi; Giorgio Annoni; David Mann; Philippe Marambaud; Davide Seripa; Daniela Galimberti; Rudolph E Tanzi; Lars Bertram; Corinne Lendon; Lars Lannfelt; Federico Licastro; Dominique Campion; Margaret A Pericak-Vance; Hilkka Soininen; Christine Van Broeckhoven; Annick Alpérovitch; Agustin Ruiz; M Ilyas Kamboh; Philippe Amouyel
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

5.  CALHM1 controls the Ca²⁺-dependent MEK, ERK, RSK and MSK signaling cascade in neurons.

Authors:  Ute Dreses-Werringloer; Valérie Vingtdeux; Haitian Zhao; Pallavi Chandakkar; Peter Davies; Philippe Marambaud
Journal:  J Cell Sci       Date:  2013-01-23       Impact factor: 5.285

6.  The P86L common allele of CALHM1 does not influence risk for Alzheimer disease in Japanese cohorts.

Authors:  Ken Inoue; Noriko Tanaka; Fumio Yamashita; Yoshie Sawano; Takashi Asada; Yu-Ichi Goto
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-03-05       Impact factor: 3.568

7.  No association between CALHM1 variation and risk of Alzheimer disease.

Authors:  Ryan L Minster; F Yesim Demirci; Steven T DeKosky; M Ilyas Kamboh
Journal:  Hum Mutat       Date:  2009-04       Impact factor: 4.878

8.  No association between CALHM1 and risk for Alzheimer dementia in a Belgian population.

Authors:  Kristel Sleegers; Nathalie Brouwers; Karolien Bettens; Sebastiaan Engelborghs; Helen van Miegroet; Peter P De Deyn; Christine Van Broeckhoven
Journal:  Hum Mutat       Date:  2009-04       Impact factor: 4.878

9.  Lack of implication for CALHM1 P86L common variation in Italian patients with early and late onset Alzheimer's disease.

Authors:  Benedetta Nacmias; Andrea Tedde; Silvia Bagnoli; Ersilia Lucenteforte; Elena Cellini; Irene Piaceri; Bianca Maria Guarnieri; Valentina Bessi; Laura Bracco; Sandro Sorbi
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

10.  Association of CALHM1 Gene Polymorphism with Late Onset Alzheimer's Disease in Iranian Population.

Authors:  Meysam Jafari Aqdam; Koorosh Kamali; Mehdi Rahgozar; Mina Ohadi; Mehdi Manoochehri; Ali Tahami; Leila Bostanshirin; Hamid Reza Khorram Khorshid
Journal:  Avicenna J Med Biotechnol       Date:  2010-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.